BT

Biotech Turnaround Fund (BTF)

Europe, Noord-Holland, The Netherlands, Bloemendaal

Description

Biotech Turnaround Fund (BTF) B.V. is a cross-over, turnaround venture capital operating company, focusing on building a portfolio of six

Investor Profile

Biotech Turnaround Fund (BTF) has made 7 investments, with 0 in the past 12 months and 14% as lead.

Stage Focus

  • Series Unknown (43%)
  • Series D (29%)
  • Series E (14%)
  • Series A (14%)

Country Focus

  • Canada (71%)
  • United States (29%)

Industry Focus

  • Biotechnology
  • Genetics
  • Life Science
  • Medical Device
  • Pharmaceutical
  • Biopharma
  • Medical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Biotech Turnaround Fund (BTF) frequently co-invest with?

HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 4
Birchmere Ventures
North America, Pennsylvania, United States, Pittsburgh
Co-Investments: 1
BM
Europe, Southern Finland, Finland, Helsinki
Co-Investments: 1
Bay City Capital
North America, California, United States, San Francisco
Co-Investments: 2
MF
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Johnson & Johnson Development Corporation
North America, New Jersey, United States, New Brunswick
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
Deerfield Capital Management
North America, Illinois, United States, Rosamond
Co-Investments: 1
Investissement Desjardins
North America, Quebec, Canada, Montréal
Co-Investments: 3
AllianceBernstein
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Biotech Turnaround Fund (BTF)?

Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series EJan 1, 2008
Amount Raised: $30,810,000
CymaBay Therapeutics

Hayward, California, United States

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

BiopharmaBiotechnologyPharmaceutical
Series DApr 19, 2007
Amount Raised: $32,000,000
Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series DFeb 5, 2007
Amount Raised: $8,454,922
CymaBay Therapeutics

Hayward, California, United States

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

BiopharmaBiotechnologyPharmaceutical
Series AAug 29, 2003
Amount Raised: $27,000,000
Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series UnknownFeb 25, 2003
Amount Raised: $7,700,000
Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series UnknownOct 12, 2001
Amount Raised: $16,500,000
Galileo Genomics

Montreal, Quebec, Canada

Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge.

GeneticsMedicalPharmaceuticalTherapeutics
Series UnknownOct 10, 2001
Amount Raised: $16,500,000